Acitretin Plasma Levels Under Hemodialysis
18 Years
N/A
Both
Carcinoma, Squamous Cell
Trial Information
Acitretin Plasma Levels Under Hemodialysis
Acitretin is given to hemodialysis patients who have developed in-situ or invasive squamous
cell carcinoma of the skin in increasing doses up to 25 mg daily for one year. Plasma levels
of acitretin will be monitored and influence of hemodialysis on acitretin plasma levels will
be determined. Number of in-situ or invasive squamous cell carcinoma of the skin cases will
be determined.
- Trial with medicinal product
Inclusion Criteria
Inclusion criteria:
- Hemodialyis patients with at least one case of in-situ or invasive squamous cell
carcinoma of the skin
Exclusion criteria:
- Hepatopathy
- Pregnancy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Outcome Measure:
Plasma levels acitretin
Outcome Time Frame:
2009
Safety Issue:
No
Principal Investigator
01 Studienregister MasterAdmins
Investigator Role:
Study Director
Investigator Affiliation:
UniversitaetsSpital Zuerich
Authority:
Switzerland: Swissmedic
Study ID:
2007DR2065 EK674
NCT ID:
NCT00488384
Start Date:
June 2007
Completion Date:
June 2015
Related Keywords:
- Carcinoma, Squamous Cell
- Squamous cell carcinoma of the skin under hemodialysis
- Carcinoma
- Carcinoma, Squamous Cell
Name | Location |
|---|
